

## Special Issue

# Human Vaccines and Vaccination for Influenza and COVID-19: Past, Present and Future

### Message from the Guest Editors

This Special Issue will focus on the most up-to-date knowledge and research pertaining to influenza and coronavirus 2019 (COVID-19) vaccines in any subgroups in any populations around the world. We invite contributions in research areas including:

- Vaccine design, adjuvants, improving vaccine efficacy;
- Improving the uptake of vaccination among any subgroups in any populations, in terms of education, communication, monitoring, and experiences of initiatives to improve uptake;
- Immune response of both COVID-19 and influenza vaccines, as well as natural infections to influenza virus and SARS-coronavirus-2 among individuals;
- COVID-19 and influenza vaccine efficacy in individuals;
- Modelling vaccination strategies for COVID-19 or influenza/mathematical transmission dynamics model and vaccine strategies.

This Special Issue aims to advance our understanding of the immune response to both influenza and COVID-19 vaccination, and of the determinants that lead to improved vaccine or booster uptake among individuals. It also aims to improve our understanding of the immune response to vaccination and natural infection, as well as of vaccine efficacy and vaccination.

---

### Guest Editors

Dr. Kin On Kwok

Dr. Kin Kit Li

Dr. Arthur Tang

Wan In Wei

---

### Deadline for manuscript submissions

closed (30 September 2023)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.2  
CiteScore 8.9  
Indexed in PubMed



[mdpi.com/si/119018](https://mdpi.com/si/119018)

*Vaccines*  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.2  
CiteScore 8.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the second half of 2024).